Biotech is uniquely popular---democrats agreed to carve out exemptions in price control measures exclusively to support the industry
Brian Gormley, 12-2-2021, life science writer for the Wall Street Journal "Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding ," WSJ, https://www.wsj.com/articles/investors-say-drug-pricing-measure-may-shift-incentives-for-biotech-venture-funding-11638448200
Democratic drug-pricing measures passed by the House may steer more venture-capital funding to biological medicines, a field already drawing significant investor attention, some investors and analysts said. The roughly $2 trillion social-spending and climate bill, approved in November, enables Medicare to negotiate prices of certain older drugs it covers and introduces other measures to curb prescription-medication costs. Biological drugs, such as protein and antibody treatments, would be subject to Medicare negotiation 13 years after their market launch. Small-molecule drugs, chemical compounds typically taken as pills, would face Medicare negotiation after nine years. Companies refusing to negotiate would face a 95% excise tax on the sales of the drug. Medicare negotiations wouldn’t begin until 2025, and would be limited to 10 drugs initially, with the number increasing each year thereafter, rising to 100 by 2030. Negotiations would be restricted to the top-selling medicines in Medicare that have no generic competition. The bill also would cap annual drug-price increases at the rate of inflation. The Senate plans to consider the bill this month. The White House, which supports the drug-pricing measures, has billed them as making medications more affordable while preserving drugmakers’ ability to be rewarded for breakthroughs.